WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a leading organ transplant company, announced today that it has entered into a definitive agreement to be acquired by Getinge. This strategic acquisition will enhance Getinge’s global healthcare portfolio to also address needs in solid organ transplantation.

马萨诸塞州沃尔瑟姆市。-（商业新闻短讯）--领先的器官移植公司Paragonix Technologies今天宣布，它已经签署了一份由Getinge收购的最终协议。

Getinge’s global reach will expand access of Paragonix’s innovative organ transplant technologies to new markets while also creating opportunities for combining the organ containment and blood perfusion technologies of the two companies for new innovations. Paragonix and Getinge share a vision to deliver market-leading solutions across the entire spectrum of transplant care..

Getinge的全球影响力将扩大Paragonix创新器官移植技术进入新市场的机会，同时也为将两家公司的器官遏制和血液灌注技术结合起来进行新创新创造机会。Paragonix和Getinge的共同愿景是在整个移植护理领域提供市场领先的解决方案。

Paragonix has led the way in developing a platform of groundbreaking organ preservation technologies, driving a shift within the clinical transplant community and redefining the standard of care in organ transplantation. Today, Paragonix is the leading US cardiothoracic organ preservation technology provider and is rapidly expanding in abdominal transplantation.

Paragonix率先开发了一个开创性的器官保存技术平台，推动了临床移植界的转变，并重新定义了器官移植的护理标准。如今，Paragonix是美国领先的心胸器官保存技术提供商，并在腹部移植领域迅速扩张。

Paragonix has developed a robust portfolio to meet the needs of the transplant community including leading clinical research initiatives, smart digital logistics platforms, and national clinical services networks. By integrating this leadership in transplantation with Getinge's extensive resources and global distribution network, the acquisition will accelerate the availability of this transformative medical technology.

Paragonix开发了一个强大的投资组合，以满足移植界的需求，包括领先的临床研究计划，智能数字物流平台和国家临床服务网络。通过将这一移植领域的领先地位与Getinge广泛的资源和全球分销网络相结合，此次收购将加速这一变革性医疗技术的可用性。

Today’s agreement will also foster the creation of new technologies addressing critical global healthcare needs..

今天的协议还将促进创造新技术，满足关键的全球医疗保健需求。

“Since our inception, Paragonix’s primary focus has been on improving patient outcomes and increasing the number of successful transplants. We have dedicated ourselves to providing clinicians and their patients with best-in-class solutions while also developing comprehensive clinical data for all solid organs.

“自成立以来，Paragonix的主要重点一直是改善患者预后和增加成功移植的数量。我们致力于为临床医生及其患者提供一流的解决方案，同时还为所有实体器官开发全面的临床数据。

Our success is a testament to our team’s passion, commitment, and relentless pursuit of excellence. We are excited to join Getinge to bring our innovations, technologies, and services to underserved patient populations worldwide,” said Dr. Lisa Anderson, Founder, President & CEO of Paragonix. “Each day, we are inspired to deliver novel, life-changing innovations to the transplant and donation communities.

我们的成功证明了我们团队的激情、承诺和对卓越的不懈追求。Paragonix创始人、总裁兼首席执行官丽莎·安德森博士表示：“我们很高兴加入Getinge，为全球服务不足的患者群体带来我们的创新、技术和服务。”。“每天，我们都受到鼓舞，为移植和捐赠社区提供新颖的，改变生活的创新。

We express our deepest gratitude to the clinical and donation community for the opportunity to serve.”.

我们对临床和捐赠界提供的服务机会深表感谢。”。

“Paragonix, as a developer, manufacturer, and service provider in the organ transplant industry has established itself as a pioneer in organ transplantation, providing a novel approach to organ preservation, transport and procurement,” said Elin Frostehav, President Acute Care Therapies at Getinge. “Teaming up with Paragonix’s talented team and proven technology is not just a strategic fit for Getinge, it is a catalyst to redefine the market standard in transplantation.

“Paragonix作为器官移植行业的开发商、制造商和服务提供商，已成为器官移植领域的先驱，为器官保存、运输和采购提供了一种新颖的方法，”Getinge急性护理治疗总裁Elin Frostehav说。“与Paragonix的天才团队和成熟的技术合作不仅是Getinge的战略选择，也是重新定义移植市场标准的催化剂。

By leveraging our expertise in the acute heart and lung support segment and providing access to our existing global sales network, we hope to expand the reach of this technology.”.

通过利用我们在急性心肺支持领域的专业知识，并提供对我们现有全球销售网络的访问，我们希望扩大这项技术的覆盖面。”

The Boards of Directors of both Paragonix and Getinge have approved the transaction, pending the satisfaction of customary closing conditions. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.

Paragonix和Getinge的董事会已经批准了这项交易，等待惯例的交割条件得到满足。

Sheppard, Mullin, Richter & Hampton LLP is serving as legal advisor, Knobbe Martens Olson & Bear LLP is serving as Intellectual Property counsel, and UBS Investment Bank Securities is serving as exclusive financial advisor to Paragonix. In March 2023, Paragonix partnered with Signet Healthcare Partners, a leading healthcare growth equity firm, to support the company’s growth and strategic objectives..

Sheppard，Mullin，Richter&Hampton LLP担任法律顾问，Knobbe Martens Olson&Bear LLP担任知识产权顾问，UBS Investment Bank Securities担任Paragonix的独家财务顾问。2023年3月，Paragonix与领先的医疗保健增长股本公司Signet Healthcare Partners合作，支持公司的增长和战略目标。

About Paragonix Technologies

关于Paragonix Technologies

Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients.

Paragonix Technologies是器官移植行业的领先开发商、制造商和服务提供商，建立了一种新的器官保存方法。Paragonix Technologies提供先进的器官保存（“AOP”）设备，在供体和受体患者之间的旅程中保护供体器官。

Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution.

我们的FDA认证和CE标记的设备结合了临床证明和医学上值得信赖的冷藏技术，可以在运输过程中对器官进行前所未有的物理和热保护。所有Paragonix AOP设备都与我们新颖的数字应用程序天然集成，为寻求安全集中解决方案的移植团队提供实时器官跟踪数据和监控物流。

For more information, visit www.paragonix.com..

有关更多信息，请访问www.paragonix.com。

Follow us on Twitter: @ParagonixSherpa

在推特上关注我们：@ParagonixSherpa

Connect with us on LinkedIn: Paragonix Technologies

在LinkedIn上与我们联系：Paragonix Technologies

Like Us on Facebook: Paragonix Technologies

就像我们在脸书上一样：Paragonix Technologies

About Getinge

关于Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science.

Getinge坚信每个人和社区都应该获得尽可能最好的护理，为医院和生命科学机构提供产品和解决方案，旨在改善临床效果和优化工作流程。该产品包括重症监护、心血管手术、手术室、无菌处理和生命科学的产品和解决方案。

Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries. For more information, visit www.getinge.com..

Getinge在全球拥有约12000名员工，产品销往135多个国家。有关更多信息，请访问www.getinge.com。